Exploring the relationships between hormone receptor, HER2 status, and bone involvement in the first distant metastases of in Chinese breast cancer patients who lacked HER2 targeted therapy

Table 2 Logistic regression on bone involvement

Variable	Class	Univariate			Multivariate ^a
Variable	Class	OR	95%CI	P	OR	95%CI	P
BC age (years)	< 40	1.575	( 0.786- 3.157)	0.201	1.280	( 0.589- 2.741)	0.525
	< 50	1.415	( 0.746- 2.686)	0.288	1.118	( 0.543- 2.300)	0.762
	< 60	1.189	( 0.624- 2.265)	0.599	1.065	( 0.521- 2.175)	0.863
	≥ 60	1.000		ref	1.000		ref
T stage ^b	T1	1.000		ref	1.000		ref
	T2	0.883	( 0.546- 1.429)	0.614	0.827	( 0.492- 1.392)	0.475
	T3-4	0.943	( 0.515- 1.727)	0.850	0.833	( 0.423- 1.638)	0.596
N stage ^b	N0	1.000		ref	1.000		ref
N stage ^b	N1-3	0.805	( 0.531- 1.219)	0.306	0.892	( 0.539- 1.476)	0.656
Pathology	IDC	1.120	( 0.675- 1.895)	0.661	1.149	( 0.491- 2.688)	0.749
Pathology	other	1.000		ref	1.000		ref
Tumor grade	I—II	1.000		ref	1.000		ref
	III	1.113	( 0.685- 1.809)	0.666	1.013	( 0.595- 1.726)	0.962
	unknown	1.845	( 0.486- 1.469)	0.550	0.598	( 0.232- 1.537)	0.285
LVI	yes	0.965	( 0.551- 1.690)	0.902	1.106	( 0.605- 2.019)	0.744
	no	1.000		ref	1.000		ref
	unknown	0.981	( 0.614- 1.567)	0.935	1.115	( 0.641- 1.940)	0.699
Chemotherapy	yes	1.273	( 0.495- 3.274)	0.617	2.015	( 0.603- 6.740)	0.255
Chemotherapy	no	1.000		ref	1.000		ref
RT	yes	1.115	( 0.756- 1.644)	0.584	1.096	( 0.690- 1.741)	0.699
RT	no	1.000		ref	1.000		ref
HR/ET compliance	HR + /full	2.203	( 1.358- 3.574)	0.001	2.329	( 1.316- 4.124)	0.004
	HR + /non, partial	2.095	(1.264- 3.472)	0.004	2.317	(1.330- 4.036)	0.003
	HR −	1.000		ref	1.000		ref
HER2	positive	0.787	( 0.518- 1.198)	0.264	0.827	( 0.516- 1.327)	0.431
	negative	1.000		ref	1.000		ref
	undetermined	0.523	( 0.254- 1.077)	0.079	0.534	( 0.245- 1.166)	0.115

DM Distant metastasis, BC Breast cancer, ref. reference, OR Odd ratio, CI Confidence interval, DFS Disease-free survival, IDC Invasive ductal carcinoma, LVI Lymphovascular invasion, RT Radiotherapy, HR Hormone receptor, HER2 Human epidermal growth factor receptor 2, ET Endocrine therapy
^a Final covariates included BC diagnosis age, diagnosis calendar year after 2010, tumor laterality, tumor quadrant, T stage, N stage, tumor pathology, tumor grade, LVI, chemotherapy, RT, and categorical disease-free time
^b Patients who had missing or unknown value were included in models, however, their ORs with insignificant p values were not tabulated

ISSN: 1471-2407